Atrial Fibrillation in Patients Receiving Ibrutinib

  • STATUS
    Recruiting
  • participants needed
    60
  • sponsor
    European Georges Pompidou Hospital
Updated on 6 February 2023
tyrosine
ibrutinib

Summary

Ibrutinib (a tyrosine kinase inhibitor targeting Bruton) is a standard of treatment in haematology. According to retrospective data, atrial fibrillation and systemic hypertension are common ibrutinib-related advserse events. The investigators aim at prospectively establishing the incidence of thesedrug related advsere events through clinical monitoring and attempt at identifying populations at risk.

Details
Condition Lymphoma, Non-Hodgkin's Lymphoma, Mantle cell lymphoma, Mantle cell lymphoma, Chronic Lymphocytic Leukemia, Lymphocytic Leukemia, Chronic, Chronic Lymphocytic Leukemia, Lymphocytic Leukemia, Chronic, Non-Hodgkin's Lymphoma
Clinical Study IdentifierNCT04407845
SponsorEuropean Georges Pompidou Hospital
Last Modified on6 February 2023

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note